Medacta Group Beheer

Hoe is Francesco Siccardi's beloning veranderd ten opzichte van Medacta Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	€56m
Mar 31 2024	n/a	n/a	€52m
Dec 31 2023	€2m	€396k	€47m
Sep 30 2023	n/a	n/a	€49m
Jun 30 2023	n/a	n/a	€50m
Mar 31 2023	n/a	n/a	€48m
Dec 31 2022	€2m	€372k	€46m
Sep 30 2022	n/a	n/a	€47m
Jun 30 2022	n/a	n/a	€47m
Mar 31 2022	n/a	n/a	€49m
Dec 31 2021	€2m	€354k	€52m
Sep 30 2021	n/a	n/a	€54m
Jun 30 2021	n/a	n/a	€57m
Mar 31 2021	n/a	n/a	€47m
Dec 31 2020	€1m	€339k	€37m
Sep 30 2020	n/a	n/a	€24m
Jun 30 2020	n/a	n/a	€10m
Mar 31 2020	n/a	n/a	€11m
Dec 31 2019	€843k	€247k	€12m

Compensatie versus markt: De totale vergoeding ($USD 2.02M ) Francesco } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 1.43M ).

Compensatie versus inkomsten: De vergoeding van Francesco is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Francesco Siccardi (47 yo)

6yrs

Tenure

€1,861,824

Compensatie

Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alberto Siccardi	Founder & Non Executive Chairman	6.8yrs	€352.21k	10.18% CHF 230.8m
Francesco Siccardi	Chief Executive Officer	6yrs	€1.86m	19.88% CHF 450.5m
Corrado Farsetta	Chief Financial Officer	13.8yrs	geen gegevens	geen gegevens
Gianluca Olgiati	Senior Director of Global Marketing	no data	geen gegevens	geen gegevens
Asif Hussain	Chief People Officer	no data	geen gegevens	geen gegevens
Alessandro Siccardi	Chief Supply Chain Officer	8.8yrs	geen gegevens	19.78% CHF 448.3m
Filippo Cappelli	Head of IT	no data	geen gegevens	geen gegevens
Giovanni Galli	Chief Commercial Officer	no data	geen gegevens	geen gegevens
Massimiliano Bernardoni	Chief Innovation Officer	no data	geen gegevens	geen gegevens
Donato Cortesi	Secretary of the Board	no data	geen gegevens	geen gegevens
Antonio Di Brino	Group Vice President of Finance & Tax	no data	geen gegevens	geen gegevens

11.3yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MOVE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 11.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Alberto Siccardi	Founder & Non Executive Chairman	6.8yrs	€352.21k	10.18% CHF 230.8m
Victor Balli	Lead Independent Director	5.8yrs	€231.19k	0.013% CHF 284.0k
Riccardo Braglia	Independent Director	3.9yrs	€128.89k	0.16% CHF 3.7m
Philippe Weber	Independent Director	5.7yrs	€152.33k	geen gegevens
Maria Siccardi Tonolli	Non-executive Director	6.8yrs	€137.62k	19.78% CHF 448.3m

5.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MOVE wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).

Medacta Group Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Insufficient new directors

Medacta Group SA, Annual General Meeting, May 25, 2021

Recent updates

Is Medacta Group (VTX:MOVE) A Risky Investment?

First half 2024 earnings released: EPS: €1.91 (vs €1.46 in 1H 2023)

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Now 20% undervalued after recent price drop

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dividend of CHF0.55 announced

Full year 2023 earnings: EPS and revenues miss analyst expectations

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Insufficient new directors

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Medacta Group SA to Report Q4, 2023 Results on Feb 02, 2024

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

First half 2023 earnings released: EPS: €1.46 (vs €1.28 in 1H 2022)

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Upcoming dividend of CHF0.54 per share at 0.5% yield

Is Medacta Group (VTX:MOVE) A Risky Investment?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Medacta Group SA to Report Fiscal Year 2022 Results on Feb 03, 2023

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Medacta Group SA to Report Q2, 2023 Results on Sep 22, 2023

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

First half 2022 earnings released: EPS: €1.28 (vs €1.49 in 1H 2021)

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Medacta Group SA Provides Revenue Guidance for the Year 2022

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group SA Approves Distribution

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Consensus forecasts updated

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Full year 2021 earnings: EPS misses analyst expectations

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Medacta Launches 360° (Anterior and Posterior) Cervical Platform, Highlighting MySpine Cervical, a Further Enhancement to the MySolutions Personalized Ecosystem

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

First half 2021 earnings released: EPS €1.49 (vs €0.48 in 1H 2020)

Medacta Group SA Confirms Revenue Guidance for the Year 2021

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Medacta Announces Successful Completion of First Reverse Shoulder Arthroplasties Using NextAR Augmented Reality Surgical Platform

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

Medacta Announces First U.S. Surgery with the New M.U.S.T. Lt System in Minimally Invasive Spine Surgery

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Full year 2020 earnings released: EPS €1.86 (vs €0.59 in FY 2019)

Medacta Announces the Launch of MySpine for S2-Alar-Iliac Fixation and Further Enhances its MySolutions Personalized Ecosystem

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Medacta Adds the MyHip Planner and the MyHip Verifier Tools to Its Medicine Solutions for Hip Replacement

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

New 90-day high: CHF103

Medacta Group SA to Report Q2, 2021 Final Results on Sep 10, 2021

New 90-day high: CHF91.60

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Medacta Group SA, Annual General Meeting, May 25, 2021

Medacta Announces Successful Completion of the First TKA Surgery in the U.S. with NextAR Augmented Reality-Based Surgical Platform